Grail IPO
Grail was a biotechnology company focused on developing blood-based tests for early cancer detection using circulating tumor DNA. The company developed the Galleri test, a multi-cancer early detection screening test that can identify over 50 types of cancer from a single blood draw.
Key Facts
| Industry | Liquid Biopsy |
| Founded | 2016 |
| Headquarters | Menlo Park, CA |
| Employees | ~1,500 |
| Website | grail.com |
| Funding | Acquired by Illumina for $7.1B in 2021 |
About Grail
Grail developed the Galleri test, a multi-cancer early detection blood test that can screen for over 50 types of cancer through analysis of circulating cell-free DNA. The company's technology represents a significant advancement in liquid biopsy capabilities, using machine learning algorithms to detect cancer signals in blood samples and predict the tissue of origin for positive results.
Originally spun out from Illumina, Grail attracted significant attention and investment for its potential to revolutionize cancer screening and early detection. The company completed large-scale clinical studies to validate its technology and received FDA breakthrough device designation. However, Grail was reacquired by Illumina in 2021 for $7.1 billion, though regulatory challenges have since complicated this ownership structure, with ongoing discussions about potential divestiture due to antitrust concerns.
IPO Status
Grail was acquired by Illumina in 2021 for approximately $7.1 billion, though the acquisition faced significant regulatory challenges. The company had previously been spun out from Illumina in 2016 and had raised substantial private funding, achieving a valuation of over $3 billion before the acquisition. The acquisition was controversial and faced antitrust scrutiny from regulators in both the US and Europe, who were concerned about vertical integration in the genomics market. As a result of regulatory pressure, Illumina was required to divest Grail, and the company was spun out again as an independent entity in 2024.
Competitors
Frequently Asked Questions
Does Grail have a stock?
Grail has not had a traditional IPO. The company was acquired by Illumina in 2021 but was later spun out again due to regulatory requirements.
When is the Grail IPO date?
There is currently no confirmed IPO date for Grail following its recent spin-out from Illumina.
How can I buy Grail stock?
Grail stock is not currently available for purchase on public markets following its complex ownership changes.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts